OncoMatch/Clinical Trials/NCT03193567
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Is NCT03193567 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HEKT cell for non small cell lung cancer.
Treatment: HEKT cell — The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
KARNOFSKY 0–1
Demographics
Prior therapy
Must have received: standard chemotherapy
failed in previous standard chemotherapy
Must have received: targeted therapy
failed in previous...targeted therapy
Lab requirements
Kidney function
adequate organ functions; severe renal dysfunction excluded
Liver function
adequate organ functions; severe hepatic dysfunction excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03193567 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard chemotherapy and targeted therapy.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages